The 128 pregnant women received Arexvy, which is also an RSV vaccine, just not the one which is FDA approved for administration during pregnancy. Arexvy is only approved for administration in adults over 60 years of age.
The only RSV vaccine approved for pregnant women is Abrysvo.
The administration errors were reported to the agency’s Vaccine Adverse Event Reporting System, but actual onset of side effects from the vaccine errors were described as “nonserious”, according to the Center for Infectious Disease Research and Policy at the University of Minnesota in Minneapolis.
In its email to clinicians, CDC recommends anyone who administered the incorrect vaccine should give a dose of Abrysvo which is approved for pregnant people during weeks 32 through 36 of pregnancy to protect infants.
Editors note: This article was updated with revised information, Jan. 26 at 8:39 a.m. CT.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.